Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Chronic Heart Failure

Free Subscription Articles published in J Cardiovasc Pharmacol Retrieve available abstracts of 87 articles: HTML format

Single Articles

April 2024
1. POLLESELLO P
   Repetitive treatments with inotropes in advanced heart failure.
   J Cardiovasc Pharmacol. 2024 Apr 2. doi: 10.1097/FJC.0000000000001569.
   PubMed    
   
   
   
2. 
   The Role of SGLT2 Inhibitors on Heart Failure Outcomes in Nondiabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Erratum.
   J Cardiovasc Pharmacol. 2024;83:359.
   PubMed    
   
   
   March 2024
3. ZHANG X, Wang Z, Zhang L, Zhao X, et al
   Comparative effectiveness and safety of intermittent, repeated or continuous use of levosimendan, milrinone, or dobutamine in patients with advanced heart failure: a network and single-arm meta-analysis.
   J Cardiovasc Pharmacol. 2024 Mar 25. doi: 10.1097/FJC.0000000000001561.
   PubMed     Abstract available
   
   
   
4. ZOHORI BAHRAMI HS, Hasselbalch RB, Soholm H, Thomsen JH, et al
   First-in-man trial of beta3-adrenoceptor agonist treatment in chronic heart failure - impact on diastolic function.
   J Cardiovasc Pharmacol. 2024 Mar 5. doi: 10.1097/FJC.0000000000001545.
   PubMed     Abstract available
   
   
   January 2024
5. HUANG Y, Zhou H, Fang C, Ma L, et al
   Cost-Effectiveness of New Quadruple Therapy Compared With Standard Treatment for Patients With Heart Failure in China.
   J Cardiovasc Pharmacol. 2024;83:86-92.
   PubMed     Abstract available
   
   
   December 2023
6. SCOMA CB, Lee DH, Money D, Eichelberger G, et al
   The Impact of Midodrine On Guideline-Directed Medical Therapy in Patients Admitted with Systolic Heart Failure.
   J Cardiovasc Pharmacol. 2023 Dec 21. doi: 10.1097/FJC.0000000000001532.
   PubMed     Abstract available
   
   
   November 2023
7. SILVETTI S, Pollesello P, Belletti A
   Repeated levosimendan infusions in the management of advanced heart failure: review of the evidence and meta-analysis of the effect on mortality.
   J Cardiovasc Pharmacol. 2023 Nov 22. doi: 10.1097/FJC.0000000000001506.
   PubMed     Abstract available
   
   
   
8. SUN Q, Cui W, Zhang X, Tian Y, et al
   A Systematic Review and Meta-analysis of Renin-angiotensin Inhibitors and Angiotensin Receptor Neprilysin Inhibitors in Preventing Recurrence after Atrial Fibrillation Ablation.
   J Cardiovasc Pharmacol. 2023 Nov 22. doi: 10.1097/FJC.0000000000001517.
   PubMed     Abstract available
   
   
   
9. LAI M, Lam JC, Radosevich JJ, Patanwala AE, et al
   Levels of Albumin and Impact on Loop Diuretic and Albumin Co-administration in Heart Failure (LILAC-HF).
   J Cardiovasc Pharmacol. 2023 Nov 17. doi: 10.1097/FJC.0000000000001513.
   PubMed     Abstract available
   
   
   
10. KOMMU S
    The Role of SGLT2 Inhibitors on Heart Failure Outcomes in Nondiabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2023 Nov 15. doi: 10.1097/FJC.0000000000001511.
    PubMed     Abstract available
    
    
    
11. ZHANG X, Wang N, Fu P, An Y, et al
    Dapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction Remodeling and Dysfunction by Elevating beta-Hydroxybutyrate-activated Citrate Synthase.
    J Cardiovasc Pharmacol. 2023;82:375-388.
    PubMed     Abstract available
    
    
    October 2023
12. CANTRELL AC, Zeng H, Chen JX
    The therapeutic potential of targeting ferroptosis in the treatment of mitochondrial cardiomyopathies and heart failure.
    J Cardiovasc Pharmacol. 2023 Oct 10. doi: 10.1097/FJC.0000000000001496.
    PubMed     Abstract available
    
    
    
13. JAFREE E, Del Buono MG, Canada JM, Carbone S, et al
    Interleukin-1 Inhibition for the Prevention and Treatment of Heart Failure.
    J Cardiovasc Pharmacol. 2023 Oct 10. doi: 10.1097/FJC.0000000000001497.
    PubMed     Abstract available
    
    
    
14. CAMILLI M, Ballacci F, Giordano F, Minotti G, et al
    Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Heart Failure in China: a new pillar in our pockets, but at what price?
    J Cardiovasc Pharmacol. 2023 Oct 10. doi: 10.1097/FJC.0000000000001498.
    PubMed     Abstract available
    
    
    September 2023
15. BUONPANE A, Biondi-Zoccai G, Versaci F
    Molecular insights on ischemic heart failure: from core genes to hearts.
    J Cardiovasc Pharmacol. 2023 Sep 26. doi: 10.1097/FJC.0000000000001486.
    PubMed    
    
    
    
16. LIN L, Zicheng L, Shaohua G
    Post-acute myocardial infarction heart failure core genes and relevant signaling pathways.
    J Cardiovasc Pharmacol. 2023 Sep 6. doi: 10.1097/FJC.0000000000001481.
    PubMed     Abstract available
    
    
    
17. BROCKMOLLER J, Ivanoski S, Hundack L, Blohm JH, et al
    Clinical and hemodynamic improvement in pulmonary hypertension after switching to sacubitril/valsartan in heart failure patients with preserved ejection fraction.
    J Cardiovasc Pharmacol. 2023 Sep 1. doi: 10.1097/FJC.0000000000001477.
    PubMed     Abstract available
    
    
    
18. PITT B, Rosenson RS
    Statins in patients with established heart failure: Time for reflection.
    J Cardiovasc Pharmacol. 2023 Sep 1. doi: 10.1097/FJC.0000000000001475.
    PubMed    
    
    
    July 2023
19. PARK S, Chang J, Hong SP, Jin ES, et al
    Impact of Trimetazidine on the Incident Heart Failure Following Coronary Artery Revascularization.
    J Cardiovasc Pharmacol. 2023 Jul 11. doi: 10.1097/FJC.0000000000001453.
    PubMed     Abstract available
    
    
    June 2023
20. HU WS, Lin CL
    Angiotensin receptor-neprilysin inhibitor versus renin-angiotensin system inhibitor for dementia risk in patients with heart failure.
    J Cardiovasc Pharmacol. 2023 Jun 30. doi: 10.1097/FJC.0000000000001451.
    PubMed     Abstract available
    
    
    
21. AHMAD F, Karim A, Khan J, Qaisar R, et al
    Statin therapy induces gut leakage and neuromuscular disjunction in patients with chronic heart failure.
    J Cardiovasc Pharmacol. 2023 Jun 27. doi: 10.1097/FJC.0000000000001445.
    PubMed     Abstract available
    
    
    
22. MANILALL A, Mokotedi L, Gunter S, Le Roux R, et al
    Tumor Necrosis Factor-alpha Mediates Inflammation-induced Early-Stage Left Ventricular Systolic Dysfunction.
    J Cardiovasc Pharmacol. 2023;81:411-422.
    PubMed     Abstract available
    
    
    May 2023
23. AUGUSTIN N, Alvarez C, Kluger J
    The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review.
    J Cardiovasc Pharmacol. 2023 May 26. doi: 10.1097/FJC.0000000000001439.
    PubMed     Abstract available
    
    
    April 2023
24. HU WS, Lin CL
    Association of heart failure patients with and without sacubitril-valsartan use with incident cancer risk.
    J Cardiovasc Pharmacol. 2023 Apr 28. doi: 10.1097/FJC.0000000000001433.
    PubMed     Abstract available
    
    
    
25. NAKATANI D, Dohi T, Hikoso S, Tanaka A, et al
    Relationship between Canagliflozin, Sodium Glucose Cotransporter 2 Inhibitor, and Hematopoietic Effects in Patients with Diabetes and Mild Heart Failure: Results from the CANDLE trial.
    J Cardiovasc Pharmacol. 2023 Apr 18. doi: 10.1097/FJC.0000000000001430.
    PubMed     Abstract available
    
    
    March 2023
26. ZHANG H, Huetteman AT, Reyes EA, Appelbaum JS, et al
    Effects of sacubitril-valsartan in Patients with Various Types of Heart Failure: A Meta-Analysis.
    J Cardiovasc Pharmacol. 2023 Mar 31. doi: 10.1097/FJC.0000000000001421.
    PubMed     Abstract available
    
    
    
27. KUANG N, Shu B, Yang F, Li S, et al
    TRAIL or TRAIL-R2 as a predictive biomarker for mortality or cardiovascular events: A systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2023 Mar 9. doi: 10.1097/FJC.0000000000001415.
    PubMed     Abstract available
    
    
    February 2023
28. ZHENG S, Zhang Y, Gu L, Ma K, et al
    Renal Safety of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2023;81:93-103.
    PubMed     Abstract available
    
    
    January 2023
29. XIE Y, Wei Y, Li D, Pu J, et al
    Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value.
    J Cardiovasc Pharmacol. 2023;81:4-14.
    PubMed     Abstract available
    
    
    November 2022
30. MOYSIDIS DV, Kartas A, Samaras A, Papazoglou AS, et al
    Prescription rates and prognostic implications of optimally-targeted guideline-directed medical treatment in heart failure and atrial fibrillation Insights from the MISOAC-AF trial.
    J Cardiovasc Pharmacol. 2022 Nov 22. doi: 10.1097/FJC.0000000000001390.
    PubMed     Abstract available
    
    
    
31. POLLESELLO P, Papp Z
    The future for inotropes in heart failure. Don't throw the baby out with the bathwater!
    J Cardiovasc Pharmacol. 2022 Nov 7. pii: 00005344-990000000-00123.
    PubMed    
    
    
    October 2022
32. LOPES WA, Reck HB, Okawa RTP
    Does Intensity Really Matter to Improve Cardiorespiratory Fitness in Patients With Heart Failure With Preserved Ejection Fraction?
    J Cardiovasc Pharmacol. 2022;80:493-495.
    PubMed    
    
    
    
33. DAGAN M, Lankaputhra M, Yeung T, Tee SL, et al
    Incidence and Predictors of Eosinophilic Myocardial Hypersensitivity in Patients Receiving Home Dobutamine.
    J Cardiovasc Pharmacol. 2022;80:623-628.
    PubMed     Abstract available
    
    
    September 2022
34. 
    Sacubitril/Valsartan Improves Sexual Function and Fibrosis of the Clitoral and Vaginal Tissues in Female Spontaneously Hypertensive Rats: Erratum.
    J Cardiovasc Pharmacol. 2022;80:489.
    PubMed    
    
    
    
35. JI M, Li Y, Liu Y, Ma G, et al
    Vaspin Ameliorates Cardiac Remodeling by Suppressing Phosphoinositide 3-Kinase/Protein Kinase B Pathway to Improve Oxidative Stress in Heart Failure Rats.
    J Cardiovasc Pharmacol. 2022;80:442-452.
    PubMed     Abstract available
    
    
    
36. WEI W, Smrcka AV
    Subcellular beta-Adrenergic Receptor Signaling in Cardiac Physiology and Disease.
    J Cardiovasc Pharmacol. 2022;80:334-341.
    PubMed     Abstract available
    
    
    
37. STEINBERG SF
    N-Tertaining a New Signaling Paradigm for the Cardiomyocyte beta 1 -Adrenergic Receptor.
    J Cardiovasc Pharmacol. 2022;80:328-333.
    PubMed     Abstract available
    
    
    
38. BORGES JI, Ferraino KE, Cora N, Nagliya D, et al
    Adrenal G Protein-Coupled Receptors and the Failing Heart: A Long-distance, Yet Intimate Affair.
    J Cardiovasc Pharmacol. 2022;80:386-392.
    PubMed     Abstract available
    
    
    August 2022
39. GALE SE, Nguyen B, Dunn SP, Kellison E, et al
    Management of Iron Deficiency in Heart Failure: A Review of Evidence.
    J Cardiovasc Pharmacol. 2022 Aug 23. pii: 00005344-990000000-00108.
    PubMed     Abstract available
    
    
    July 2022
40. YANG G, Gai X, Han M, Gao F, et al
    Aberrant circulating SNHG1 serves as a biomarker to distinguish acute myocardial infarction and construction of a risk model for secondary heart failure.
    J Cardiovasc Pharmacol. 2022 Jul 11. pii: 00005344-990000000-00043.
    PubMed    
    
    
    June 2022
41. LI S, Huang Y, Li T, Zhu X, et al
    Glucocorticoids promote Na+ excretion in the renal epithelia of heart failure rats by suppressing transporter proteins involved in acute sodium loading.
    J Cardiovasc Pharmacol. 2022 Jun 13. pii: 00005344-990000000-00064.
    PubMed     Abstract available
    
    
    May 2022
42. GUO Y, Xiao C, Zhao K, He Z, et al
    Physical Exercise Modalities for the Management of Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2022;79:698-710.
    PubMed     Abstract available
    
    
    
43. CLEMENTS JN
    Development and Current Role of Sodium Glucose Cotransporter Inhibition in Cardiorenal Metabolic Syndrome.
    J Cardiovasc Pharmacol. 2022;79:593-604.
    PubMed     Abstract available
    
    
    
44. OYESOMI ET, Tabrizchi R
    Heart and Sodium-Glucose Cotransporter 2 Inhibitors: A Sodium Dilemma.
    J Cardiovasc Pharmacol. 2022;79:641-643.
    PubMed    
    
    
    
45. BILLINGSLEY H, Dixon D, Yehya A, Carbone S, et al
    Sleeve Gastrectomy Reduces BMI and Pill Count in Patients With LVAD.
    J Cardiovasc Pharmacol. 2022;79:644-645.
    PubMed    
    
    
    April 2022
46. MARCUSOHN E, Borreda I, Hellman Y, Habib M, et al
    IV Sodium Ferric Gluconate Complex in Patients with Iron Deficiency hospitalized due to Acute Heart Failure- Investigator initiated, Randomized controlled trial.
    J Cardiovasc Pharmacol. 2022 Apr 29. pii: 00005344-990000000-00038.
    PubMed     Abstract available
    
    
    
47. GITTO M, Kotinas AS, Terzi R, Oliva A, et al
    Biochemical efficacy of sodium-glucose cotransporter 2 inhibitors by cardiovascular risk profile and volume status in a real-world diabetic population.
    J Cardiovasc Pharmacol. 2022 Apr 14. pii: 00005344-990000000-00025.
    PubMed     Abstract available
    
    
    
48. POLLESELLO P, Kivikko M
    Renal impairment in patients with acute heart failure: Are inotropes safe?
    J Cardiovasc Pharmacol. 2022 Apr 1. pii: 00005344-990000000-00016.
    PubMed    
    
    
    
49. RUSSO V, Ammendola E, Gasperetti A, Bottino R, et al
    Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients.
    J Cardiovasc Pharmacol. 2022;79:472-478.
    PubMed     Abstract available
    
    
    March 2022
50. CUI X, Wang Z, Dong X, Cheng Z, et al
    Comparative effectiveness and safety of milrinone and levosimendan as initial inotrope therapy in acute heart failure patients with renal dysfunction.
    J Cardiovasc Pharmacol. 2022 Mar 4. pii: 00005344-990000000-00031.
    PubMed     Abstract available
    
    
    February 2022
51. DEL BUONO MG, Damonte JI, Chiabrando JG, Markley R, et al
    Effect of IL-1 Blockade with Anakinra on Heart Failure Outcomes in Patients with Anterior versus Non-Anterior STEMI.
    J Cardiovasc Pharmacol. 2022 Feb 11. pii: 00005344-900000000-98049.
    PubMed     Abstract available
    
    
    January 2022
52. MCCANDLESS MG, Altara R, Booz GW, Kurdi M, et al
    What Role do Mitochondria have in Diastolic Dysfunction? Implications for Diabetic Cardiomyopathy and Heart Failure with Preserved Ejection Function (HFpEF).
    J Cardiovasc Pharmacol. 2022 Jan 21. pii: 00005344-900000000-98053.
    PubMed     Abstract available
    
    
    
53. KIM Y, Byun S, Kim HY, Kim DB, et al
    Long-term beta-blocker therapy after myocardial infarction without heart failure in the reperfusion era - systemic review and meta-analysis.
    J Cardiovasc Pharmacol. 2022 Jan 18. pii: 00005344-900000000-98062.
    PubMed     Abstract available
    
    
    
54. AL-ANI MA, Murray MR, Taha MB, Meece L, et al
    Impact of Laparoscopic Sleeve Gastrectomy on Cardiovascular Pharmacotherapy in Left Ventricular Assist Device Patients.
    J Cardiovasc Pharmacol. 2022 Jan 17. pii: 00005344-900000000-98060.
    PubMed     Abstract available
    
    
    December 2021
55. YEUNG T, Dagan M, Lankaputhra M, Cieslik L, et al
    Levosimendan and continuous outpatient support with inotropes (COSI) in patients with advanced heart failure: a single-centre descriptive study.
    J Cardiovasc Pharmacol. 2021 Dec 31. pii: 00005344-900000000-98078.
    PubMed     Abstract available
    
    
    
56. CHEN PW, Trivedi A, Lee E, Dutta S, et al
    Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients with Heart Failure with Reduced Ejection Fraction.
    J Cardiovasc Pharmacol. 2021 Dec 27. pii: 00005344-900000000-98069.
    PubMed     Abstract available
    
    
    
57. KAWADA K, Kubo T, Ishida T, Jobu K, et al
    Assisted Living and Medication Adherence in Super-Aged Patients With Heart Failure in the Japanese population.
    J Cardiovasc Pharmacol. 2021 Dec 27. pii: 00005344-900000000-98064.
    PubMed     Abstract available
    
    
    November 2021
58. ZHENG RJ, Wang Y, Tang JN, Duan JY, et al
    Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials.
    J Cardiovasc Pharmacol. 2021 Nov 22. pii: 00005344-900000000-98109.
    PubMed     Abstract available
    
    
    
59. VIDER E, Sapir R, Mosseri E, Gavioli E, et al
    Current perspectives of the use of Sodium Glucose Transport-2 Inhibitors for patients with heart failure and chronic kidney disease.
    J Cardiovasc Pharmacol. 2021 Nov 3. pii: 00005344-900000000-98119.
    PubMed     Abstract available
    
    
    
60. FERNANDES C, Antonio N, Marinho V, Milner J, et al
    Digoxin in patients with advanced heart failure and sinus rhythm submitted to cardiac resynchronization therapy- is there any benefit?
    J Cardiovasc Pharmacol. 2021 Nov 3. pii: 00005344-900000000-98116.
    PubMed     Abstract available
    
    
    
61. AMRITPHALE A
    Right Heart Failure Management: the Achilles heel.
    J Cardiovasc Pharmacol. 2021 Nov 3. pii: 00005344-900000000-98115.
    PubMed    
    
    
    
62. JIMENEZ-BLANCO BRAVO M, Valle A, Gayan Ordas J, Del Prado Diaz S, et al
    Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry).
    J Cardiovasc Pharmacol. 2021;78:e662-e668.
    PubMed     Abstract available
    
    
    October 2021
63. MASARONE D, Melillo E, Errigo V, Martucci ML, et al
    Haemodynamic Effects of Levosimendan in Outpatients with Advanced Heart Failure: An Echocardiographic Pilot Study.
    J Cardiovasc Pharmacol. 2021 Oct 23. pii: 00005344-900000000-98126.
    PubMed     Abstract available
    
    
    
64. YANG Y, Shen C, Lu J, Fu G, et al
    Sacubitril/valsartan in the treatment of right ventricular dysfunction in patients with heart failure with reduced ejection fraction: a real-world study.
    J Cardiovasc Pharmacol. 2021 Oct 21. pii: 00005344-900000000-98124.
    PubMed     Abstract available
    
    
    
65. ADIE SK, Abdul-Aziz AA, Ketcham SW, Moles VM, et al
    Considerations for inotrope and vasopressor use in critically ill patients with pulmonary arterial hypertension.
    J Cardiovasc Pharmacol. 2021 Oct 6. pii: 00005344-900000000-98139.
    PubMed     Abstract available
    
    
    September 2021
66. DU X, Ma Z, Li L, Zhong X, et al
    Nicorandil Decreases Renal Injury in Patients With Coronary Heart Disease Complicated With Type I Cardiorenal Syndrome.
    J Cardiovasc Pharmacol. 2021;78:e675-e680.
    PubMed     Abstract available
    
    
    
67. DIXON DL, Billingsley HE, Canada JM, Trankle CR, et al
    Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study.
    J Cardiovasc Pharmacol. 2021;78:407-410.
    PubMed     Abstract available
    
    
    
68. YANG M, Wang X, Wang T
    Regulation of Mitochondrial Function by Noncoding RNAs in Heart Failure and Its Application in Diagnosis and Treatment.
    J Cardiovasc Pharmacol. 2021;78:377-387.
    PubMed     Abstract available
    
    
    August 2021
69. HUANG Y, Zhang Y, Ma L, Zhou H, et al
    Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021;78:202-210.
    PubMed     Abstract available
    
    
    July 2021
70. SHRESTHA DB, Budhathoki P, Sedhai YR, Karki P, et al
    SGLT-2 inhibitors in heart failure: An updated systematic review and meta-analysis of 13 randomized clinical trials including 14618 patients with heart failure.
    J Cardiovasc Pharmacol. 2021 Jul 9. pii: 00005344-900000000-98175.
    PubMed     Abstract available
    
    
    
71. DEL BUONO MG, Damonte JI, Trankle CR, Bhardwaj H, et al
    Sacubitril/Valsartan for the prevention and treatment post-infarction heart failure: ready to use?
    J Cardiovasc Pharmacol. 2021 Jul 2. pii: 00005344-900000000-98179.
    PubMed    
    
    
    June 2021
72. ADIE SK, Ketcham SW, Abdul-Aziz AA, Thomas MP, et al
    Characteristics of heart failure patients with or without hypotension when transitioning from nitroprusside to sacubitril-valsartan.
    J Cardiovasc Pharmacol. 2021 Jun 21. pii: 00005344-900000000-98191.
    PubMed     Abstract available
    
    
    
73. WATSON K, Kukin A, Wasik AK, Shulenberger CE, et al
    Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease.
    J Cardiovasc Pharmacol. 2021;77:685-698.
    PubMed     Abstract available
    
    
    
74. MARUNOUCHI T, Nakashima M, Ebitani S, Umezu S, et al
    Hsp90 Inhibitor Attenuates the Development of Pathophysiological Cardiac Fibrosis in Mouse Hypertrophy via Suppression of the Calcineurin-NFAT and c-Raf-Erk Pathways.
    J Cardiovasc Pharmacol. 2021;77:822-829.
    PubMed     Abstract available
    
    
    
75. PASCALE JV, Lucchesi PA, Garcia V
    Unraveling the Role of 12- and 20- HETE in Cardiac Pathophysiology: G-Protein-Coupled Receptors, Pharmacological Inhibitors, and Transgenic Approaches.
    J Cardiovasc Pharmacol. 2021;77:707-717.
    PubMed     Abstract available
    
    
    
76. YE G, Wang S, Peng D
    Effects of SGLT2 Inhibitor on Ischemic Events Stemming From Atherosclerotic Coronary Diseases: A Systematic Review and Meta-analysis With Trial Sequential Analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021;77:787-795.
    PubMed     Abstract available
    
    
    May 2021
77. NANDKEOLYAR S, Ryu R, Mohammed A, Cordero-Caban K, et al
    A Review of Inotropes and Inopressors for Effective Utilization in Patients with Acute Decompensated Heart Failure.
    J Cardiovasc Pharmacol. 2021 May 28. pii: 00005344-900000000-98208.
    PubMed     Abstract available
    
    
    April 2021
78. LONG YX, Cui DY, Kuang X, Hu S, et al
    Effect of Levosimendan on Ventricular Systolic and Diastolic Functions in Heart Failure Patients: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98238.
    PubMed     Abstract available
    
    
    February 2021
79. HAN Y, Hua S, Chen Y, Yang W, et al
    Circulating PGLYRP1 levels as a potential biomarker for coronary artery disease and heart failure.
    J Cardiovasc Pharmacol. 2021 Feb 18. pii: 00005344-900000000-98269.
    PubMed     Abstract available
    
    
    December 2020
80. RERICK L, Elston C, Kester J, Montepara C, et al
    Evaluation of sacubitril/valsartan initiation in outpatient heart failure patients.
    J Cardiovasc Pharmacol. 2020 Dec 1. doi: 10.1097/FJC.0000000000000966.
    PubMed     Abstract available
    
    
    November 2020
81. WOHLFORD GF, Van Tassell BW, Billingsley HE, Kadariya D, et al
    A Phase IB, Randomized, Double-Blinded, Dose Escalation, Single Center, Repeat-Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects with NYHA II-III Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2020 Nov 17. doi: 10.1097/FJC.0000000000000931.
    PubMed     Abstract available
    
    
    
82. GAO D, David C, Rosa MM, Costa J, et al
    The risk of mortality associated with opioid use in patients with acute heart failure: systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2020 Nov 17. doi: 10.1097/FJC.0000000000000954.
    PubMed     Abstract available
    
    
    
83. GIUSEPPE DEL BUONO M, Crea F, Versaci F, Biondi-Zoccai G, et al
    NLRP3 inflammasome: a new promising therapeutic target to treat heart failure.
    J Cardiovasc Pharmacol. 2020 Nov 2. doi: 10.1097/FJC.0000000000000946.
    PubMed    
    
    
    October 2020
84. BERNIER TD, Buckley LF
    Cardiac Myosin Activation for the Treatment of Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2020 Oct 30. doi: 10.1097/FJC.0000000000000929.
    PubMed     Abstract available
    
    
    
85. HU J, Wu Y, Zhou X, Wang X, et al
    Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population.
    J Cardiovasc Pharmacol. 2020;76:445-451.
    PubMed     Abstract available
    
    
    July 2020
86. PAPP Z, Agostoni P, Alvarez J, Bettex D, et al
    Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.
    J Cardiovasc Pharmacol. 2020;76:4-22.
    PubMed     Abstract available
    
    
    June 2020
87. DENG T, Wei Z, Gael A, Deng X, et al
    Higenamine Improves Cardiac and Renal Fibrosis in Rats With Cardiorenal Syndrome via ASK1 Signaling Pathway.
    J Cardiovasc Pharmacol. 2020;75:535-544.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.